Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation (clinicaltrials.gov) - Sep 3, 2026 - P2 | N=124 | Recruiting | Sponsor: Hannah Choe, MD | Initiation date: Jun 2026 ➔ Jan 2026
Trial initiation date • Chronic Myelomonocytic Leukemia • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Myelodysplastic Syndrome • Oncology • Transplantation • HLA-B • HLA-C • HLA-DRB1
|